Pronunciation:
lan-a-del-ue-mab
Trade Name(s)
Ther. Class.
antiangioedema agents
Pharm. Class.
kallikrein inhibitors
monoclonal antibodies
Prevention of hereditary angioedema (HAE) attacks.
Acts as a selective, reversible inhibitor of kallikrein, thereby inhibiting its action in initiating bradykinin production, part of the cascade of events in HAE.
Therapeutic Effect(s):
Reduction in number of HAE attacks.
Absorption: Well absorbed following subcutaneous administration.
Distribution: Well distributed to tissues.
Metabolism and Excretion: Unknown.
Half-life: 14–15 days.
TIME/ACTION PROFILE (plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Subcut | unknown | 4–5 days | unknown |
Contraindicated in:
Use Cautiously in:
Derm: rash
GI: diarrhea, ↑ liver enzymes
Local: injection site reactions
Neuro: headache, dizziness
Resp: upper respiratory infection
MS: myalgia
Misc: HYPERSENSITIVITY REACTIONS (including anaphylaxis)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Drug-Drug
None known.
SUBQ (Adults and Children ≥12 yr): 300 mg every 2 wk. If patient has been free of attacks for >6 mo, can adjust regimen to 300 mg every 4 wk.
Solution for injection: 150 mg/mL
Monitor for signs and symptoms of severe hypersensitivity reactions (hives, urticaria, chest tightness, wheezing, hypotension, anaphylaxis) during or after injection.
Advise patient to notify health care professional immediately if signs and symptoms of hypersensitivity reaction occur.
Decrease in frequency, intensity, and duration of symptoms of HAE.